Gastrointestinal manifestations of scleroderma: Recent progress in evaluation, pathogenesis, and management

Current Rheumatology Reports

Volumn 14, Issue 1, 2012, Pages 22-29

  Gyger, Genevieve ^a   Baron, Murray ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Anorectal; Colon; Gastrointestinal; Gastrointestinal reflux; Malnutrition; Scleroderma; Small bowel; Small intestinal bacterial overgrowth; Stomach; Systemic sclerosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFALEXIN; CHLORAMPHENICOL; CIPROFLOXACIN; DOMPERIDONE; DOXYCYCLINE; ERYTHROMYCIN; LONG ACTING DRUG; METOCLOPRAMIDE; METRONIDAZOLE; MINOCYCLINE; NITAZOXANIDE; NORFLOXACIN; OCTREOTIDE; PROTON PUMP INHIBITOR; RIFAXIMIN; TETRACYCLINE;

ANORECTAL DISEASE; ANTIBIOTIC THERAPY; ARTICLE; BEDTIME DOSAGE; CANCER RISK; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS DISEASE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; MALNUTRITION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; PSEUDOOBSTRUCTION; QUALITY OF LIFE; RISK FACTOR; SCLERODERMA; SMALL INTESTINE DISEASE; STOMACH ANTRUM VASCULAR ECTASIA; STOMACH DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; TREND STUDY;

GASTROINTESTINAL DISEASES; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 84856945805     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0217-3     Document Type: Article

References (57)

1. T Ponge SV des Bruley 2002 Atteintes digestives sclérodermiques La Revue du Praticien 52 196 200
2. PJ Clements R Becvar AA Drosos, et al. 2003 Assessment of gastrointestinal involvement Clin Exp Rheumatol 21 S15 S18 12889216 1:STN:280:DC%2BD3szlslaisQ%3D%3D
3. VD Steen TA Medsger Jr 2000 Severe organ involvement in systemic sclerosis with diffuse scleroderma Arthritis Rheum 43 2437 2444 11083266 10.1002/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U 1:STN:280:DC%2BD3M%2FktFequw%3D%3D
4. RW Sjogren 1994 Gastrointestinal motility disorders in scleroderma Arthritis Rheum 37 1265 1282 7945489 10.1002/art.1780370902 1:STN:280: DyaK2M%2Fjt1agug%3D%3D (Pubitemid 24320743)
5. K Jaovisidha ME Csuka UA Almagro, et al. 2005 Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature Semin Arthritis Rheum 34 689 702 15692963 10.1016/j.semarthrit.2004. 08.009 (Pubitemid 40193368)
6. A Forbes I Marie 2009 Gastrointestinal complications: the most frequent internal complications of systemic sclerosis Rheumatology (Oxford) 48 Suppl 3 iii36 iii39 10.1093/rheumatology/ken485
7. K Franck-Larsson W Graf A Rönnblom 2009 Lower gastrointestinal symptoms and quality of life in patients with systemic sclerosis: a population-based study Eur J Gastroenterol Hepatol 21 m176 m182 10.1097/MEG.0b013e32831dac75
8. BD Thombs M Hudson SS Taillefer, et al. 2008 Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis Arthritis Rheum 4 504 509 10.1002/art.23524 (Pubitemid 351563532)
9. A Attar 2002 Atteintes digestives au cours de la sclérodermie Ann Med Interne (Paris) 153 260 264
10. E Savarino M Bazzica P Zentilin, et al. 2009 Gastroesophageal reflux and pulmonary fibrosis in scleroderma. A study using pH-impedance monitoring Am J Respir Crit Care Med 179 408 413 19096004 10.1164/rccm.200808-1359OC
11. G Lock A Holstege B Lang, et al. 1997 Gastrointestinal manifestations of progressive systemic sclerosis Am J Gastroenterol 92 763 771 9149182 1:STN:280:DyaK2s3ptlWhuw%3D%3D (Pubitemid 27200787)
12. I Marie H Lévesque P Ducrotté, et al. 1999 Atteinte de l'intestin grêle au cours de la sclérodermie systémique Rev Med Interne 20 504 513 10422142 10.1016/S0248-8663(99)80085-X 1:STN:280:DyaK1MzltFSnsA%3D%3D
13. WA D'Angelo JF Fries AT Masi, et al. 1969 Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls Am J Med 46 428 440 5780367 10.1016/0002-9343(69) 90044-8
14. RW Sjogren 1996 Gastrointestinal features of scleroderma Curr Opin Rheumatol 8 569 575 9018461 10.1097/00002281-199611000-00012 1:STN:280:DyaK2s7ntFajtA%3D%3D (Pubitemid 27044447)
15. L Hendel T Kobayasi M Petri 1987 Ultrastructure of the small intestinal mucosa in progressive systemic sclerosis (PSS) Acta Pathol Microbiol Immunol Scand A 95 41 46 3825544 1:STN:280:DyaL2s7lt1egug%3D%3D (Pubitemid 17022555)
16. CP Denton CM Black DJ Abraham 2006 Mechanisms and consequences of fibrosis in systemic sclerosis Nat Clin Pract Rheumatol 2 134 144 16932673 10.1038/ncprheum0115 (Pubitemid 43771821)
17. L Hendel T Ammitzboll K Dirksen M Petri, et al. 1986 Collagen components in the duodenal and rectal mucosa in progressive systemic sclerosis and other diseases Acta Derm Venereol 66 220 224 2426898 1:STN:280:DyaL283ptFyquw%3D%3D (Pubitemid 16115862)
18. WL Treacy AH Baggenstoss CH Slocumb, et al. 1963 Scleroderma of the esophagus. A correlation of histologic and physiologic findings Ann Intern Med 59 351 356 14065952 1:STN:280:DyaF2c%2FitlGrtg%3D%3D
19. S Howe EY Eaker JE Sallustio, et al. 1994 Antimyenteric neuronal antibodies in scleroderma J Clin Invest 94 761 770 8040331 10.1172/JCI117395 1:CAS:528:DyaK2cXltlaisL0%3D (Pubitemid 24251009)
20. EY Eaker JG Kuldau GN Verne, et al. 1999 Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model J Lab Clin Med 133 551 556 10360629 10.1016/S0022- 2143(99)90184-1 1:STN:280:DyaK1M3oslektg%3D%3D (Pubitemid 29257217)
21. Y Kawaguchi Y Nakamura I Matsumoyo, et al. 2009 Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility Ann Rheum Dis 68 710 714 18762475 10.1136/ard.2008.096545 1:CAS:528:DC%2BD1MXls1Chu7w%3D To clarify the pathogenesis of GI tract involvement in SSc, the occurrence of autoantibody for M3R was investigated in 14 SSc patients and 70 healthy controls. Anti-M3R antibody was found more frequently in patients with SSc, suggesting that M3R-mediated enteric cholinergic neurotransmission may provide a pathogenic mechanism for GI tract dysmotility in SSc
22. J Singh V Mehendiratta F Del Galdo, et al. 2009 Immunoglobulins from scleroderma patients inhibit the muscarinic receptor activation in internal anal sphincter smooth muscle cells Am J Physiol Gastrointest Liver Physiol 297 206 213 This study determined the effect of SSc IgGs on the muscarinic receptor activation by bethanecol in smooth muscle cells and smooth muscle strips from rat IAS. The results suggest that SSc GI dysmotility may be caused by autoantibodies that inhibit the muscarinic neurotransmission in smooth muscle cells of the GI tract, opening a door for possible treatment of GI SSc disease directed at the removal or neutralization of the antibodies
23. EC Ebert 2008 Gastric and enteric involvement in progressive systemic sclerosis J Clin Gastroenterol 42 5 12 18097282 10.1097/MCG.0b013e318042d625
24. TJ Poirier GB Rankin 1972 Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases Am J Gastroenterol 58 30 44 4537959 1:STN:280:DyaE383ktFSiug%3D%3D
25. Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int. 2010 Aug 14. [Epub ahead of print].
26. L Hendel E Hage J Hendel, et al. 1992 Omeprazole in the long-term treatment of severe gastro-esophageal reflux disease in patients with systemic sclerosis Aliment Pharmacol Ther 6 565 577 1420748 10.1111/j.1365-2036.1992. tb00571.x 1:STN:280:DyaK3s%2Fkt1CqtQ%3D%3D
27. I Marie P Ducrotte P Denis, et al. 2006 Oesophageal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy Aliment Pharmacol Ther 24 11-12 1593 1601 17206947 10.1111/j.1365-2036.2006.03180.x 1:CAS:528:DC%2BD2sXpslahtg%3D%3D (Pubitemid 44915207)
28. J Wipff R Coriat M Masciocchi, et al. 2011 Outcome of Barrett's oesophagus related to systemic sclerosis: a 3 year EULAR Scleroderma Trials and Research prospective follow-up study Rheumatology 50 8 1440 1444 21415021 10.1093/rheumatology/ker110
29. American Thoracic Society 2000 Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement Am J Resp Crit Care Med 161 646 664
30. G Raghu TD Freudenberg S Yang, et al. 2006 High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic fibrosis Eur Respir J 27 136 142 16387946 10.1183/09031936.06.00037005 1:STN:280:DC%2BD28%2FgtFensw%3D%3D (Pubitemid 43092677)
31. JZ Appel 3rd SM Lee MG Hartwig, et al. 2007 Characterization of the innate immune response to chronic aspiration in a novel rodent model Respir Res 8 87 18042282 10.1186/1465-9921-8-87
32. E Savarino M Bazzica P Zentilin, et al. 2009 Gastroesophageal reflux and pulmonary fibrosis in scleroderma. A study using pH-impedance monitoring Am J Respir Crit Care Med 179 408 413 19096004 10.1164/rccm.200808-1359OC In this prospective study, 40 patients with SSc underwent pulmonary HRCT scan and 24-hour impedance pH monitoring off PPI therapy. Patients with ILD on HRCT had more reflux episodes and more reflux reaching the proximal esophagus, suggesting a relationship between GER and ILD. Whether the development of ILD in patients with SSc can be prevented via reflux-reducing treatments needs to be investigated
33. RB Christmann AU Wells VL Capelozi, et al. 2010 Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence Semin Arthritis Rheum 40 241 249 20494406 10.1016/j.semarthrit.2010.03.002 In this review, the authors summarize clinical, radiologic, histopathologic, and treatment aspects of GER in SSc-ILD. They describe the association of GER with SSc-ILD strongly supported by several studies. They recommend aggressive treatment for reflux in all patients with ILD, keeping in mind, however, that future studies need to be conducted to prove long-term benefit of GER treatment in ILD
34. G Raghu ST Yang C Spada, et al. 2006 Sole treatment of acid gastroesophageal reflux in idiopathic fibrosis: a case series Chest 129 3 794 800 16537884 10.1378/chest.129.3.794
35. RBC de Souza CTL Borges VL Capelozzi, et al. 2009 Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis Respiration 77 389 397 18799868 10.1159/000156958 In this prospective study, 28 patients with SSc-ILD went for open lung biopsy. A total of 21% of the patients had an isolated CLF, a novel histologic pattern described in idiopathic interstitial pneumonia. This pattern was also found in 84% of the patients with a predominant NSIP. A high frequency of esophageal abnormality was observed in both groups of CLF and NSIP, suggesting that the CLF pattern could be associated with GER
36. ME De Carvalho RA Kairalla VL Capelozzi, et al. 2002 Centrilobular fibrosis: a novel histologic pattern of idiopathic interstitial pneumonia Pathol Res Pract 198 577 583 12440779 10.1078/0344-0338-00305 (Pubitemid 35244054)
37. M Brumit E Carter 2002 Pathologic quiz case: patient with systemic sclerosis and anemia Arch Pathol Lab Med 126 375 376 11860320 (Pubitemid 34208136)
38. I Marie P Ducrotte M Antoinietti, et al. 2008 Watermelon stomach in systemic sclerosis: its incidence and management Aliment Pharmacol Ther 28 412 421 18498445 10.1111/j.1365-2036.2008.03739.x 1:STN:280:DC%2BD1crivFOjsw%3D%3D (Pubitemid 352033274)
39. KM Ingraham MS O'Brien M Shenn, et al. 2010 Gastric antral vascular ectasia in systemic sclerosis: demographics and disease predictors J Rheumatol 37 603 607 20080908 10.3899/jrheum.090600 To date, general characteristics of patients with watermelon stomach have rarely been studied. In this retrospective study, it was found that GAVE was associated with early diffuse SSc, rapid skin progression, and anti-RNA pol III antibodies
40. CP Sellinger YS Ang 2008 Gastric antral vascular ectasia (GAVE): an update on clinical presentation, pathophysiology and treatment Digestion 77 131 137 10.1159/000124339 (Pubitemid 351556391)
41. SW Schulz M O'Brien M Maqsood, et al. 2009 Improvement of severe systemic sclerosis-associated gastric antral vascular ectasia following immunosuppressive treatment with intravenous cyclophosphamide J Rheumatol 36 1653 1656 19605670 10.3899/jrheum.081247 1:CAS:528:DC%2BD1MXhtV2hu7jK
42. RJ Stratton CL King MA Stroud, et al. 2006 'Malnutrition Universal Screening Tool' predicts mortality and length of hospital stay in acutely ill elderly Br J Nutr 95 325 330 16469149 10.1079/BJN20051622 1:CAS:528: DC%2BD28XjtF2qsrw%3D
43. M Baron M Hudson R Steele 2009 Malnutrition is common in systemic sclerosis: results from the Canadian Scleroderma Research Group Database J Rheumatol 36 2737 2743 19833750 10.3899/jrheum.090694
44. L Krause M O Becker CS Brueckner, et al. 2010 Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis Ann Rheum Dis 69 1951 1957 20511612 10.1136/ard.2009.123273 This study showed that 55.7% of SSc patients had malnutrition, that the best predictors of malnutrition were low predicted forced vital capacity and high-NT-pro-BNP, and that malnutrition was associated with disease activity and severity. Also, severe malnutrition was a predictor of SSc-related mortality
45. MY Jaffrin 2009 Body composition determination by bioimpedance: an update Curr Opin Clin Nutr Metab Care 12 482 486 19494768 10.1097/MCO.0b013e32832da22c
46. M Baron P Bernier L-F Côté, et al. 2010 Screening and management for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel Clin Exp Rheumatol 28 Suppl. 58 42 46 This article is the result of a meeting between experts in areas of nutrition, speech pathology, oral health in SSc, and SSc and gastroenterology. Recommendations regarding screening of malnutrition, evaluation, interventions, and follow-up were made
47. D Khanna RD Hays P Maranian, et al. 2009 Reliability and validity of the University of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument Arthritis Rheum 61 1257 1263 19714600 10.1002/art.24730
48. G Perlemuter P Cacoub S Chaussade, et al. 1999 Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases Arthritis Rheum 42 545 549 10.1002/1529-0131(199907)42:7<1545::AID- ANR30>3.0.CO;2-T (Pubitemid 30265614)
49. Khanna D. Gastrointestinal involvement in systemic sclerosis. In: Font J, Ramos-Casals M, Rodés J, eds. Digestive Involvement in Systemic Autoimmune Diseases. New York: Elsevier:51-61.
50. GC Nikou C Toumpanakis C Katsiari, et al. 2007 Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients J Clin Rheumatol 13 119 123 17551375 10.1097/RHU. 0b013e3180645d2a (Pubitemid 46884197)
51. GN Verne EY Eaker E Hardy, et al. 1995 Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction Dig Dis Sci 40 1892 1901 7555439 10.1007/BF02208652 1:CAS:528:DyaK2MXpsFaisbg%3D
52. M Brown A Teubner J Shaffer, et al. 2008 Home parenteral nutrition-an effective and safe long-term therapy for systemic sclerosis-related intestinal failure Rheumatology (Oxford) 47 176 179 10.1093/rheumatology/kem329 1:CAS:528:DC%2BD1cXht1Shtrw%3D (Pubitemid 351168227)
53. AH Mawdsley 2006 Patient perception of UK scleroderma services-results of an anonymous questionnaire Rheumatology 45 1573 17043046 10.1093/rheumatology/ kel337 1:STN:280:DC%2BD28notlGisw%3D%3D (Pubitemid 44817069)
54. AF Engel MA Kamm IC Talbot 1994 Progressive systemic sclerosis of the internal anal sphincter leading to passive faecal incontinence Gut 35 857 859 8020821 10.1136/gut.35.6.857 1:STN:280:DyaK2c3pt1ShsQ%3D%3D
55. Thoua NM, Schizas A, Forbes A, et al. Internal anal sphincter atrophy in patients with systemic sclerosis. Rheumatology (Oxford). 2011 Apr 18. [Epub ahead of print].
56. CG Roberts LK Hummers WJ Ravich, et al. 2006 A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma) Gut 55 1697 1703 16527835 10.1136/gut.2005.086074 1:STN:280:DC%2BD28nosFOluw%3D%3D (Pubitemid 44893564)
57. NM Thoua M Abdel-Halim C Denton, et al. 2009 Faecal incontinence in systemic sclerosis is related to sphincter atrophy and reflex dysfunction Gut 58 A90 10.1136/gut.2008.155473